methylphenidate has been researched along with Dyskinesia, Medication-Induced in 26 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It has been known to have side effects such as dyskinesia, but this case details the emergence of dystonia and dyskinesia when the simultaneous use of methylphenidate and a phenothiazine was followed by withdrawal of the phenothiazine." | 7.66 | Methylphenidate, neuroleptics and dyskinesia-dystonia. ( Chapel, J; Husain, A; Malek-Ahmadi, P, 1980) |
| "In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems." | 7.66 | Methylphenidate-induced chorea: case report and pharmacologic implications. ( Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| "To determine if repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter, would augment the effects of oral levodopa in patients with Parkinson disease." | 5.12 | Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. ( Carlson, NE; Carter, JH; Nutt, JG, 2007) |
| " We report two cases of an adverse effect of dyskinesia and bruxism when MPH was given to children maintained on valproic acid." | 3.70 | Adverse response to methylphenidate in combination with valproic acid. ( Gara, L; Roberts, W, 2000) |
| " It has been known to have side effects such as dyskinesia, but this case details the emergence of dystonia and dyskinesia when the simultaneous use of methylphenidate and a phenothiazine was followed by withdrawal of the phenothiazine." | 3.66 | Methylphenidate, neuroleptics and dyskinesia-dystonia. ( Chapel, J; Husain, A; Malek-Ahmadi, P, 1980) |
| "In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems." | 3.66 | Methylphenidate-induced chorea: case report and pharmacologic implications. ( Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| " Both groups were assessed for dyskinetic symptoms at ten weekly intervals as dosage was phased out in the neuroleptic group." | 2.66 | Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. ( Aman, MG; Singh, NN, 1985) |
| "Methylphenidate is a short-acting stimulant." | 1.39 | Methylphenidate-induced acute orofacial and extremity dyskinesia. ( Donmez, A; Isik, B; Orun, E; Sonmez, FM; Tas, T; Yilmaz, AE, 2013) |
| " Personal or family tic history, medication selection, or dosage was not related to onset of T/D." | 1.29 | Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. ( Adesman, AR; Goldstein, IJ; Lipkin, PH, 1994) |
| "Deanol did not produce the anticipated elevation in choline levels postulated to be one mechanism of its action." | 1.26 | Deanol acetamidobenzoate (Deaner) in tardive dyskinesia. ( Fann, WE; Stafford, JR, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (42.31) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naguy, A | 1 |
| Alrashidi, F | 1 |
| Elsori, DH | 1 |
| Waugh, JL | 1 |
| Kim, JY | 1 |
| Baik, JS | 1 |
| Yilmaz, AE | 1 |
| Donmez, A | 1 |
| Orun, E | 1 |
| Tas, T | 1 |
| Isik, B | 1 |
| Sonmez, FM | 1 |
| Senecky, Y | 1 |
| Lobel, D | 1 |
| Diamond, GW | 1 |
| Weitz, R | 1 |
| Inbar, D | 1 |
| Mendhekar, DN | 1 |
| Duggal, HS | 1 |
| Nutt, JG | 1 |
| Carter, JH | 1 |
| Carlson, NE | 1 |
| Tahiroglu, AY | 1 |
| Avci, A | 1 |
| Balázs, J | 1 |
| Besnyo, M | 1 |
| Gádoros, J | 1 |
| Hollis, CP | 1 |
| Thompson, A | 1 |
| Christensen, AV | 2 |
| Nielsen, IM | 2 |
| Gerlach, J | 1 |
| Bjørndal, N | 1 |
| Christensson, E | 1 |
| El-Defrawi, MH | 1 |
| Greenhill, LL | 1 |
| Radonjic, D | 1 |
| Lapierre, YD | 1 |
| Knott, V | 1 |
| Husain, A | 1 |
| Chapel, J | 1 |
| Malek-Ahmadi, P | 1 |
| Lieberman, JA | 3 |
| Alvir, J | 2 |
| Geisler, S | 1 |
| Ramos-Lorenzi, J | 2 |
| Woerner, M | 2 |
| Novacenko, H | 1 |
| Cooper, T | 1 |
| Kane, JM | 2 |
| Lipkin, PH | 1 |
| Goldstein, IJ | 1 |
| Adesman, AR | 1 |
| Connor, DF | 1 |
| Gara, L | 1 |
| Roberts, W | 1 |
| Jeste, DV | 1 |
| Wyatt, RJ | 1 |
| Weiner, WJ | 1 |
| Nausieda, PA | 1 |
| Klawans, HL | 1 |
| Stafford, JR | 1 |
| Fann, WE | 1 |
| Aman, MG | 1 |
| Singh, NN | 1 |
| Sarantakos, S | 1 |
| Gadaleta, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Subacute Trial of Methylphenidate in Parkinson's Disease[NCT00359723] | Phase 2 | 13 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for methylphenidate and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Prediction of outcome in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Growth Hormo | 1993 |
In search of treatment for tardive dyskinesia: review of the literature.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodop | 1979 |
4 trials available for methylphenidate and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Uptake Inhibitors; Do | 2007 |
Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
Topics: Adolescent; Adult; Blinking; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studie | 1994 |
Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, | 1985 |
Prediction of relapse in schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Blinking; Dopamine Antagonists; Dyskinesia | 1987 |
20 other studies available for methylphenidate and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Methylphenidate-induced "Moving Ear Syndrome" in a child with ADHD responding favorably to add-on propranolol.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyskinesia, | 2019 |
Acute dyskinetic reaction in a healthy toddler following methylphenidate ingestion.
Topics: Acute Disease; Central Nervous System Stimulants; Dyskinesia, Drug-Induced; Humans; Male; Methylphen | 2013 |
Adult onset methylphenidate induced dyskinesia after stroke.
Topics: Central Nervous System Stimulants; Dyskinesia, Drug-Induced; Female; Humans; Male; Methylphenidate; | 2014 |
Methylphenidate-induced acute orofacial and extremity dyskinesia.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; C | 2013 |
Isolated orofacial dyskinesia: a methylphenidate-induced movement disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Respon | 2002 |
Methylphenidate-induced rabbit syndrome.
Topics: Child; Dyskinesia, Drug-Induced; Humans; Male; Methylphenidate; Movement Disorders | 2006 |
Polypharmacy and EPS in a child; a case report.
Topics: Attention Deficit Disorder with Hyperactivity; Benztropine; Bipolar Disorder; Child; Comorbidity; Do | 2007 |
Methylphenidate-induced orofacial and extremity dyskinesia.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyskinesia, | 2007 |
Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
Topics: Acute Disease; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2007 |
Dopaminergic supersensitivity: influence of dopamine agonists and drugs used for the treatment of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Dopamine; Dose-Response Relationship, Drug; Drug Interac | 1980 |
Methylphenidate, apomorphine, THIP, and diazepam in monkeys: dopamine-GABA behavior related to psychoses and tardive dyskinesia.
Topics: Animals; Apomorphine; Chlorocebus aethiops; Diazepam; Dopamine; Drug Interactions; Dyskinesia, Drug- | 1984 |
Substituting stimulants in treating behavior disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dyskinesia, Drug-Induced; Humans; Male; Methyl | 1984 |
The effect of methylphenidate on tardive dyskinesia.
Topics: Adult; Dyskinesia, Drug-Induced; Electromyography; Humans; Methylphenidate; Middle Aged; Motor Activ | 1981 |
Methylphenidate, neuroleptics and dyskinesia-dystonia.
Topics: Asthma; Child, Preschool; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyp | 1980 |
Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Chronic Disease; | 1994 |
Stimulants and neuroleptic withdrawal dyskinesia.
Topics: Aggression; Antipsychotic Agents; Central Nervous System Stimulants; Child; Drug Therapy, Combinatio | 1998 |
Adverse response to methylphenidate in combination with valproic acid.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bruxism; Central Nervous System Stim | 2000 |
Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia.
Topics: Animals; Antiparkinson Agents; Apomorphine; Atropine; Dopamine; Drug Synergism; Dyskinesia, Drug-Ind | 1979 |
Methylphenidate-induced chorea: case report and pharmacologic implications.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Child, Preschool; Chorea; Dopa | 1978 |
Deanol acetamidobenzoate (Deaner) in tardive dyskinesia.
Topics: Choline; Cyproheptadine; Deanol; Drug Evaluation; Dyskinesia, Drug-Induced; Ethanolamines; Humans; M | 1977 |